Drug General Information
Drug ID
D00VUI
Former ID
DNC001160
Drug Name
Psoralen
Drug Type
Small molecular drug
Indication Discovery agent Phase 3 [524054]
Structure
Download
2D MOL

3D MOL

Formula
C11H6O3
Canonical SMILES
C1=CC(=O)OC2=CC3=C(C=CO3)C=C21
InChI
1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H
InChIKey
ZCCUUQDIBDJBTK-UHFFFAOYSA-N
CAS Number
CAS 66-97-7
PubChem Compound ID
PubChem Substance ID
ChEBI ID
ChEBI:27616
SuperDrug ATC ID
D05BA03
SuperDrug CAS ID
cas=000484208
Target and Pathway
Target(s) Amine oxidase [flavin-containing] B Target Info Inhibitor [535106]
Amine oxidase [flavin-containing] A Target Info Inhibitor [535106]
BioCyc Pathway Superpathway of tryptophan utilization
Tryptophan degradation via tryptamine
Dopamine degradation
Putrescine degradation III
Noradrenaline and adrenaline degradationPWY66-401:Superpathway of tryptophan utilization
Noradrenaline and adrenaline degradation
Serotonin degradation
Superpathway of melatonin degradation
Melatonin degradation II
KEGG Pathway Glycine, serine and threonine metabolism
Arginine and proline metabolism
Histidine metabolism
Tyrosine metabolism
Phenylalanine metabolism
Tryptophan metabolism
Drug metabolism - cytochrome P450
Metabolic pathways
Serotonergic synapse
Dopaminergic synapse
Cocaine addiction
Amphetamine addiction
Alcoholismhsa00260:Glycine, serine and threonine metabolism
Alcoholism
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
5-Hydroxytryptamine degredation
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
Dopamine receptor mediated signaling pathway
Pathway Interaction Database Alpha-synuclein signaling
PathWhiz Pathway Histidine Metabolism
Tyrosine Metabolism
Glycine and Serine Metabolism
Reactome Norepinephrine Neurotransmitter Release Cycle
WikiPathways Tryptophan metabolism
Dopamine metabolism
Phase 1 - Functionalization of compoundsWP706:SIDS Susceptibility Pathways
Biogenic Amine Synthesis
Oxidative Stress
Phase 1 - Functionalization of compounds
Neurotransmitter Release Cycle
Neurotransmitter Clearance In The Synaptic Cleft
Serotonin Transporter Activity
References
Ref 524054ClinicalTrials.gov (NCT01686594) PUVA Maintenance Therapy in Mycosis Fungoides. U.S. National Institutes of Health.
Ref 535106Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.